Journal
CANCERS
Volume 14, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/cancers14102353
Keywords
SLFN11; ovarian cancer; high-grade serous carcinoma; DNA-damaging agents; PARPi; chemoresistance
Categories
Funding
- Ministry of Health of the Czech Republic (MHCR) [NU21-03-00306]
- MHCR-Development of Research Organization (FNBr) [65269705]
Ask authors/readers for more resources
This review discusses the current state and potential applications of Schlafen 11 as a biomarker in ovarian cancer treatment.
Simple Summary Anticancer agents causing DNA damage are widely used in the treatment of ovarian cancer; however, predictive biomarkers capable of optimizing the selection of patients with the best likelihood of a good response have not been defined yet. The newly discovered protein Schlafen 11 was identified to have a casual association with responses to a wide range of DNA-damaging agents, including platinum compounds and PARP inhibitors. We review the current state of knowledge regarding the role of Schlafen 11 as a biomarker in ovarian cancer and its potential to identify patients not responding to the systemic treatment. Platinum-based chemotherapy has been the cornerstone of systemic treatment in ovarian cancer. Since no validated molecular predictive markers have been identified yet, the response to platinum-based chemotherapy has been evaluated clinically, based on platinum-free interval. The new promising marker Schlafen 11 seems to correlate with sensitivity or resistance to DNA-damaging agents, including platinum compounds or PARP inhibitors in various types of cancer. We provide background information about the function of Schlafen 11, its evaluation in tumor tissue, and its prevalence in ovarian cancer. We discuss the current evidence of the correlation of Schlafen 11 expression in ovarian cancer with treatment outcomes and the potential use of Schlafen 11 as the key predictive and prognostic marker that could help to better stratify ovarian cancer patients treated with platinum-based chemotherapy or PARP inhibitors. We also provide perspectives on future directions in the research on this promising marker.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available